Epitope mapping of antibodies against prostate-specific antigen with use of peptide libraries.
Materials and Methods
ANTIBODIES AND PROTEINS
The MAbs 5E4, 9C5, and 4G10 were developed with the following protocol. BALB/c mice were immunized with 10-30 [micro]g of purified PSA by intraperitoneal injection with Freund's complete adjuvant. PSA was purified from human seminal fluid as described previously (27). A booster dose of 10 [micro]g was given after 4 weeks, and then additional boosters of 100 and 150 [micro]g were given 1 and 2 days after the first booster, respectively. After the final booster, the splenic lymphoid cells of the mice were fused with the mouse myeloma cell line P3x63-Ag8.653 (American Type Culture Collection). The fused cells were harvested in HAT medium supplemented with interleukin-6 for 4 weeks, after which the cells were harvested in HT medium. PSA antibody production was screened by use of an immunofluorometric assay (IFMA) in microtiter wells coated with rabbit anti-mouse immunoglobulin. Briefly, 25 [micro]L of hybridoma supernatants plus 200 [micro]L of IFMA assay buffer (6) were incubated for 1 h in the wells, after which the wells were washed twice and 10 ng of [Eu.sup.3+]-labeled PSA in 200 [micro]L of assay buffer was added. After additional incubation for 30 min, the wells were washed four times, and 200 [micro]L of enhancement solution (Perkin-Elmer-Wallac) was added. After incubation for 5 min, the fluorescence was measured. The MAbs produced were purified by affinity chromatography using protein G columns (Amersham Biosciences).
Anti-PSA MAbs H117 and H50 were obtained from Abbott Diagnostics. Antibody 5A10 was from Perkin-Elmer-Wallac. The characteristics of the ISCBM workshop panel of anti-PSA MAbs have been described in detail elsewhere (16). Anti-phage MAb was a kind gift from Dr. Petri Saviranta (University of Turku, Turku, Finland). Anti-phage polyclonal antibody was purchased from Amersham Biosciences. Peptides were synthesized by standard Merrifield solid-phase chemistry. The phage peptide libraries were a kind gift from Dr Erkki Koivunen (University of Helsinki, Helsinki, Finland).
SELECTION OF PHAGE PEPTIDES
Screening of the phage display peptide libraries was performed essentially as described previously (28). Libraries with the structures CX7C, CX8C, CX10C, CX3CX3CX3C, and CX3CX4CX2C, where C is cysteine and X is any of the 20 naturally occurring amino acids, were used. A pool of these libraries containing [10.sup.11]-[10.sup.12] infectious particles was screened with each MAb. Briefly, a pool of phage libraries was added to the wells coated with a MAb and incubated for 3 h at 22[degrees]C during the first round of panning and for 1 h during subsequent rounds. The phage solution was removed, and the wells were washed with Tris-buffered saline (TBS; 50 mmol/L Tris-HCl, pH 7.8, 0.15 mol/L NaCl) containing 5 mL/L Tween 20. Bound phage were eluted with 0.1 mol/L glycine buffer, pH 2.2, and neutralized with 1 mol/L Tris base. The eluted phage were amplified by infection of Escherichia coli K91 kan cells and purified by precipitation with polyethylene glycol. Sequential panning with two MAbs was performed with MAb pairs known to react with the same antigenic region on PSA, including MAb pairs 5E4/H117, 9C5/H50, and 4G10/5A10. For example, the primary library was panned for two rounds using MAb 5E4, after which the eluate was amplified and panned for one round with MAb H117.
After three rounds of selection and amplification, the peptide sequences were determined by sequencing the relevant part of the viral DNA as described previously (28). Sequencing was performed with an ABI 310 Genetic Analyzer and Dye Terminator Cycle Sequencing Core Kit (PE Applied Biosystems), with the oligonucleotide 5'-CCCTCATAGTTAAGCGTAACG-3' as a primer. The amino acid sequence of each peptide isolated was analyzed for homology with PSA and other proteins by the BLASTP program using the SwissProt database. The three-dimensional model of PSA established by Villoutreix et al. (29) was visualized with the RasMol program (30).
The solid-phase antibodies used in the IFMA were coated on microtitration wells at a concentration of 5 mg/L in TBS for 16 h at 22[degrees]C. The solution was then discarded, and the wells were saturated with 10 g/L bovine serum albumin in TBS for 3 h at 22[degrees]C. The antibodies used as tracers were labeled with a [Eu.sup.3+] chelate as described previously (28). The assay buffer was TBS, pH 7.7, containing 33 [micro]mol/L bovine serum albumin and 1 /,mol/L bovine globulin.
The binding of individual phage clones to MAbs was tested by phage IFMA. In this assay, 15 [micro]L of phage ([10.sup.9]-[10.sup.10] infectious particles) and 200 [micro]L of assay buffer were added to wells coated with each MAb. After incubation for 1 h, the wells were washed and filled with 200 [micro]L of assay buffer containing 50 ng of a [Eu.sup.3+]-labeled anti-phage MAb recognizing the M13 coat protein of the phage. After incubation for 60 min, the wells were washed four times, and enhancement solution (Perkin-Elmer-Wallac) was added. Fluorescence was quantified with a 1234 DELFIA Research fluorometer (Perkin-Elmer-Wallac). The detection limit was defined as the fluorescence signal obtained with phage containing unrelated peptide +3 SD.
The binding specificity of the phage peptide to the antigen-binding regions of the mAbs was confirmed by showing that PSA inhibited the binding of phage to antibodies. Briefly, 15 [micro]L of each phage clone and 0.3-300 ng of PSA purified from seminal fluid were pipetted into a well coated with each mAb. After incubation of phage and PSA for 2 h, the protocol for phage IFMA was followed. The binding specificity of synthetic peptides was confirmed by showing that they competed with PSA for binding to antibodies. Briefly, 0-120 [micro]g of peptide in 200 [micro]L of assay buffer was pipetted into a well coated with MAb. After incubation for 1 h, 5 ng of PSA was added and incubated for 30 min. Inhibition of PSA binding was quantified by PSA IFMA as described (31).
REACTIVITY OF THE PHAGE WITH THE ISOBM WORKSHOP PANEL OF MAbs
Phage isolated by panning with the six PSA MAbs were tested for binding to 39 MAbs from the ISOBM workshop for characterization of antibodies against PSA by phage IFMA. According to the ISOBM classification, the six MAbs used for screening of the phage libraries belonged to epitope groups 1, 3, and 6 (16), which in this study are referred to as I, III, and VI, respectively. The ISOBM workshop MAbs tested included MAbs 26, 33, 68, 74, 77, 78, 85, 209, 213, 216, 223, and 230 from epitope group I; MAbs 31, 36, 57, 63, 64, 66, 72, 82, 84, 88, 89, 212, 224, and 229 from epitope group III; and MAbs 27, 29, 34, 56,65, 67, 75, 79, 210, 214, 218, 221, and 225 from epitope group VI.
IDENTIFICATION OF ANTIBODY-BINDING PEPTIDES
The MAbs studied were chosen on the basis of cross-inhibition characteristics to include three pairs of closely related antibodies. The peptides isolated with the six MAbs contained characteristic motifs and consensus amino acids (Table 1), but only 9 of 100 peptides displayed sequence identity with PSA, defined as at least three identical amino acids within a window of four amino acids. Binding of the peptides to MAbs was inhibited by PSA, showing that they were paratope specific (Fig. 1).
The epitopes of MAbs 5E4 and H117 have been mapped to the N-terminal region of PSA (amino acid residues 3-11) by synthetic peptide mapping and cross-inhibition studies (16, 20). However, most of the peptides developed against these antibodies resembled neither PSA nor each other. This indicated that the peptides recognized structures in the paratope that do not participate in antigen binding or that the epitopes were different and mainly determined by the three-dimensional structure of PSA. To identify peptides reacting with two MAbs recognizing the same epitope, we developed a sequential panning strategy. The peptides identified by this strategy using MAbs 5E4 and H117 did not resemble the peptides selected separately (Table 1). Two peptides, CPSVDGGWTC (VI-13 and VI-20) and CHSACSKHCFVHC (VI-15 and VI-22), were obtained irrespective of the order in which the MAbs were used for selection. In peptides VI-13 and VI-14, the motif GGWTC was similar to the sequence GGWEC comprising residues 3-7 in the N[H.sub.2] terminus of mature PSA (Fig. 2). Furthermore, in peptides VI-15 and VI-21, the motif CSKH was similar to the sequence CEKH comprising residues 7-10 in PSA (Fig. 2). Thus, the structures of these peptides suggest that the epitope recognized by MAbs 5E4 and H117 comprises residues 3-10 in mature PSA. All phage peptides isolated by use of MAb 5E4 alone contained the structure PXDFXFL. This motif was not present in peptides selected by MAb H117 alone, which contained the motif WXXXPXE (Table 1). Among MAb 5E4-selected peptides, peptides VI-9 and VI-12 contained the sequence EFL corresponding to PSA amino acid residues 140-142; a similar sequence, DFL, was present in four other peptides, and the FL sequence was present in all 12 peptides. A synthetic peptide (corresponding to the sequence of phage peptide VI-12) containing the EFL sequence inhibited the binding of PSA with MAb 5E4 in a dose-dependent manner (Fig. 3), confirming that this peptide and PSA bind to same site on the MAb. Among MAb H117-selected peptides, peptide VI-18 contained the PEE sequence (residues 138-140 in PSA), and the PXE motif was present in three of the four peptides. Thus, these MAbs recognize the same amino acids in region 3-10 and different amino acids from the region 138-142 (PEEFL; Fig. 2). Interestingly, in the three-dimensional model of PSA (29), the PEEFL sequence is located close to the N-terminal epitope (Fig. 4). These results suggest that amino acids 138-142 form part of a noncontinuous epitope together with amino acids 3-10 in the N-terminal region.
[FIGURE 1 OMITTED]
[FIGURE 2 OMITTED]
Group I MAbs 5A10 and 4G10 bind to an epitope specific for free PSA, which in PSA-serpin complexes is covered by the inhibitors (16,32). Some MAbs in this group have been shown to bind to linear epitopes comprising amino acids 80-91 in PSA, which form part of the so-called kallikrein loop (16, 20), but most of them react only weakly with reduced, intact PSA, suggesting that they are mainly conformation dependent. MAbs 5A10 and 4G10 inhibit each other efficiently, but MAb 4G10 has been shown to cross-react with complexed PSA approximately two- to fivefold more than does 5A10 (33, 34), suggesting that the epitopes of these MAbs are not identical. When we selected with 4G10 and sequentially with 4G10 and 5A10, we found the motifs YPFW, WWW, and PWW (Table 1), but these are not found in PSA. However, when we selected with MAb 5A10 and sequentially with 5A10 and 4G10, we frequently found the WGS and TVXXAW motifs. Peptide I-9 contained the sequence SWGSSRC, which is similar to the PSA sequence SWGSEPC (amino acids 204-210 in PSA; Fig. 2). Furthermore, WGS, WG, or GS motifs were present in 7 of 22 peptides isolated. In agreement with this, Michel et al. (21) have found by screening peptide libraries that the SWG site forms part of the epitope of MAbs specific for free PSA. Amino acids 204-207 (SWGS) form the edge of the groove containing the active site residues of PSA (29) opposite the region 80-91 on the other side of the groove. Peptide I-16 contained the sequence HPQKV, which is similar to the PSA sequence HPQKV (amino acids 164-168 in PSA), which is located adjacent to amino acids 204-207 and borders to the predicted binding site of group III MAbs (Fig. 2). It may thus form part of the epitope for MAbs specific for free PSA. Further support for the location of the epitope as predicted by phage display peptides can be obtained by analyzing whether the predicted epitope regions differ between PSA and hK2 and accounting for whether the MAb reacts with PSA only or with both PSA and hK2. hK2 shares 80% identity with PSA (11-13), and many PSA antibodies are known to recognize hK2, showing that several epitopes in PSA and hK2 are identical (16, 35). Thus, the location of the epitope of MAb 5A10 in the 164-168 region in PSA is further supported by the facts that this region differs between PSA and hK2 (HPQKV and YSEKV, respectively) and that MAb 5A10 does not react with hK2 (16). Thus, these results suggest that the epitopes for MAbs belonging to group I may comprise residues on three different loops, i.e., amino acids 80-91 (20), 164-168, and 204-207.
[FIGURE 3 OMITTED]
[FIGURE 4 OMITTED]
MAbs H50 and 9C5 bind to epitopes located remote from the active site and are considered to be mainly conformation dependent (16). These MAbs show highly similar binding characteristics, but only H50 shows strong reactivity with hK2 (16, 36). The peptides isolated by panning with MAb H50 and sequentially with MAbs H50 and 9C5 frequently contained the structures GIXXW or GYW, whereas in peptides isolated by use of MAb 9C5 and sequentially with MAbs 9C5 and H50, the NWN motif was found repeatedly. Peptides III-8 and III-9 (H50 selection) contained the sequences PGIDS and PGIRS, respectively, which are similar to the sequence PGDDS in PSA (amino acids 89-93; Fig. 2). This region partially overlaps amino acids 80-91 in PSA, which is the previously identified binding site for MAbs specific for free PSA (20). Furthermore, MAb H50 binds strongly to both PSA and hK2, but the amino acid sequence 89-93 in these differs (PGDDS and PGDDS in PSA and hK2, respectively). Thus, it is unlikely that the PGDDS sequence is part of the epitope for these MAbs. In peptide III-12 (H50 selection), the sequence PLVDN is similar to the PSA sequence PLVCN (amino acids 192-196 in PSA; Fig. 2). This sequence is identical in PSA and hK2, and it is adjacent to epitope region 151-155 in the three-dimensional model of PSA, which previously has been predicted to be a binding site for MAbs belonging to this epitope group. Thus, these results suggest that the epitopes for group III MAbs comprise at least two different loops, i.e., amino acids 151-155 (20) and 192-196.
REACTIVITY OF THE PEPTIDES WITH ISOBM MAbS
To study whether the epitopes found were recognized by other MAbs, we studied the reactivity of 19 peptides with a panel of MAbs from the ISOBM workshop. The peptides studied were isolated by sequential panning using MAb pairs 5E4/H117 (group VI), 4G10/5A10 (group I), and H50/9C5 (group III).
The reactivity of three group VI peptides showing similarity with amino acids 3-10 in PSA was studied with 13 group VI MAbs (Table 2). Seven MAbs bound to these peptides, suggesting that amino acids 3-10 in PSA form part of the epitope recognized by most MAbs in this group. Six of the MAbs did not bind any of these peptides, suggesting that these amino acids are not a major part of their epitopes or that the motif is not present in correct conformation for these MAbs.
The reactivity of six group I peptides (I-8, I-15, I-30, I-31, I-32, and I-35) was studied with 14 group I MAbs. These peptides showed highly restricted specificity and reacted only with the primary selection MAb, i.e., peptides I-8 and I-15 reacted only with MAb 5A10, and peptides I-30, I-31, I-32, and I-35 reacted only with MAb 4G10.
The reactivity of eight group III peptides was tested with 14 MAbs from epitope group III (Table 3). Some of the peptides reacted with several MAbs within this epitope group. Most of them showed unique binding patterns, but MAbs 72 and 229 may have closely related specificity because they reacted only with peptide III-15. MAb 224 reacted only with peptides III-15, -20, and -25, obtained with MAb H50 as primary selection antibody, whereas MAb 89 reacted only with peptide III-37, obtained with MAb 9C5 as primary selection MAb. Four MAbs did not bind to any of the peptides.
The main antigenic regions of PSA recognized by mouse antibodies have been studied extensively (16,17, 20, 22), but not much is known about the fine structure of the epitopes. In this study, we isolated peptides binding specifically with the paratope regions of six PSA MAbs and studied their reactivity with a large panel of PSA antibodies.
Alignment of the peptides with the PSA sequence revealed several binding motifs, but most of the isolated peptides did not resemble any part of PSA. These may represent mimotopes, i.e., antigenic mimics, or they may be structurally unrelated to PSA, reflecting the polyspecific nature of the binding region of an antibody (37). Thus, although MAbs are usually considered to be specific for a certain antigen, the paratope can also bind structures that do not resemble the original immunogen. Even if MAbs have rarely been shown to bind strongly to unrelated natural antigens, cross-reactivity with a totally unrelated protein has been observed with an antibody prepared against a synthetic peptide (38). The polyspecificity can be explained by the fact that the paratope consists of ~20 amino acids, but only a few of these participate in antigen binding, and water molecules can fill the remaining space between the paratope and epitope. Thus, the same paratope can contain several subsites for different epitopes, and amino acids in the paratope can form strong bonds with peptides unrelated to the immunogen (37, 39). The polyspecific nature of paratopes toward unrelated peptides has also been demonstrated by Keitel et al. (40) and Kramer et al. (41), who used x-ray structural data of three peptides complexed with an anti-p24 (HIV-1) MAb.
In our study, only ~10% of the peptides showed similarity with PSA. Some of these corresponded to earlier identified epitopes, whereas others contained new motifs adjacent to earlier described ones. Thus, they may well form part of the epitope. Antibodies 5E4 and H117 identified the same N-terminal epitope (amino acids 3-10) as was found in previous studies for MAbs in this group (20), but they also appeared to react with amino acids in the 138-142 region. These antibodies also react with hK2 (16), and regions 3-10 and 138-142 are identical in PSA and hK2 (11,12), further supporting the involvement of these residues in the epitopes. Results from other groups have suggested that most of the MAbs that bind both PSA and hK2 recognize nonconformational linear epitopes (35). The N-terminal part of PSA appears to form a fairly long linear N-terminal epitope (residues 3-10) and thus may be the major mediator of binding of MAbs in this group. However, regions 3-10 and 138-142 reside within 15-20 [Angstrom] from each other, and amino acids within this distance can be in contact with the paratope (37). Thus, it is conceivable that the epitopes of some group VI MAbs comprise residues 3-10 and 138-142. MAbs 5E4 and H117 bind peptides similar to PSA 3-10 and 138-142, but the epitopes around amino acids 138-142 are overlapping rather than identical. Parhami-Seren et al. (42) also identified overlapping epitopes for two related MAbs against streptokinase by screening peptide libraries.
Interestingly, in previous synthetic peptide epitope mapping studies, MAb H117 did not react with any synthetic linear peptide derived from the PSA sequence (20), although it has been shown to compete efficiently with other group VI MAbs (16). Thus, it is likely that the synthetic peptides used by Piironen et al. (20) could not adopt the correct conformation required for strong binding with MAb H117.
We also found some paratope-specific peptides showing sequence similarity with PSA, but the suggested epitope locations were not in agreement with those in previous studies. In a single peptide (III-8), the sequence identity was not compatible with previous epitope assignments, suggesting that the sequence similarity was attributable to chance.
A key factor in the protocol for isolating peptides resembling the linear epitope in the N[H.sub.2] terminus of PSA was the introduction of sequential panning with two MAbs. With this method, peptides reacting with both selection MAbs (5E4 and H117) were obtained. However, with MAb pairs 9C5/H50 and 5A10/4G10, no peptides reactive with both MAbs were found, which suggests that the epitopes for these MAbs do not contain common residues although they block the binding of each other.
Synthetic peptide mapping studies have suggested that the binding sites for MAbs specific for free PSA reside in the regions 50-69 (19) and 80-91 (20). In the study of Piironen et al. (20), all seven free-PSA MAbs reacted strongly with peptides containing the 84-91 sequence. Some binding of MAbs was observed to peptides containing the sequence 50-67, but strong reaction with these peptides was observed for only two MAbs recognizing both free and complexed PSA. Furthermore, Jette et al. (43) identified the sequence PSA 51-55 as an epitope for a "total PSA specific" MAb by use of both synthetic peptide epitope mapping and peptide library screening. Michel et al. (21) suggested on the basis of peptide library screening that the epitopes of MAbs specific for free PSA include amino acid residues from PSA regions 53-59, 145-148, and 204-207. Our results also suggested that amino acids 204-208 may form part of the epitope for such MAbs, but no peptides resembling the two other sequences were found. In the three-dimensional model, these amino acids form a relatively wide loop, and it is possible that the cyclic peptides used in our study are too tightly coiled to mimic such a loop.
No peptides that bound strongly to MAb H50 were found by Piironen et al. (20) by use of synthetic peptide epitope mapping, but the binding sites of related MAbs were mapped to the 151-155 region. We did not find any peptides with similarity to this region by screening with the two related MAbs, H50 and 9C5. However, a peptide showing similarity with the 192-196 region was identified after screening with MAb H50, and this region is adjacent to region 151-155 in the three-dimensional model of PSA. Furthermore, the 192-196 region is identical in PSA and hK2, and MAb H50 is reactive with both PSA and hK2 (16).
REACTIVITY OF THE PEPTIDES WITH ISOBM MAbS
Previous studies on reactivity of paratope-binding peptides with MAbs showing highly similar specificity suggested that peptides generally show restricted specificity toward the selection MAb (44). This was also the case with peptides to group I MAbs, which were specific for free PSA, i.e., each peptide bound only to the MAb used to isolate it. The peptides selected with group III MAbs also showed restricted specificity. Most of them bound to 1-3 of the 14 MAbs specific for this region. In contrast, the peptides selected with group VI MAbs recognized many antibodies. Two peptides bound to one-half (7 of 13) of the MAbs included. These results suggest that amino acids 3-10 form an immunodominant region that can be mimicked by the fairly short cyclic peptides. The restricted specificity of the peptides to MAbs in other groups may indicate larger variability in epitope specificity. Thus, although some epitope regions can be subgrouped by use of paratope-binding peptides, the general utility of this approach for epitope identification is limited. Many peptides bearing no relationship with the immunogen (PSA) bound strongly to the paratopes. Apparently these binding specificities are not displayed by natural human antigens, as evidenced by the very high specificity of MAbs when used for clinical purposes. However, the unexpected reactivity of a MAb to BRCA1 with semenogelin may be an example of such polyspecificity (38). A less dramatic but more common demonstration of this polyspecificity is the nonspecific inhibition of antigen-antibody binding exerted by proteins. This phenomenon contributes to the well-known matrix effect that affects all immunoassays (45). The nonspecific interactions between various proteins in clinical samples and the paratope must be much weaker that that of the specifically selected peptides, and it can usually be eliminated by diluting the sample (45).
In conclusion, this study shows that screening with peptide libraries can be used to define both linear and noncontinuous epitopes, but the assignment of an epitope region needs to be confirmed by complementary methods. Furthermore, although MAbs are highly specific when used in clinical assays, the paratope region can bind strongly to several unrelated peptide structures. However, strong nonspecific binding may be revealed only by phage display peptides, whereas it appears to be very rare in natural samples.
This work was supported by grants from the Academy of Finland, Sigfrid Jus6lius Foundation, and the Finnish Cancer Society. We thank Liisa Airas and Maarit Leinimaa for expert technical assistance.
(1.) Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995;45:8-30.
(2.) Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979;17:159-63.
(3.) Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
(4.) Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324: 1156-61.
(5.) Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan 0. A complex between prostate-specific antigen and a1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51: 222-6.
(6.) Leinonen J, Lovgren T, Vornanen T, Stenman UH. Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with [[alpha].sub.1]-antichymotrypsin. Clin Chem 1993;39:2098-103.
(7.) Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, Stenman UH. Measurement of the complex between prostate-specific antigen and a, -protease inhibitor in serum. Clin Chem 1999;45:814-21.
(8.) Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, Rannikko S, et al. Characterization and immunological determination of the complex between prostate-specific antigen and [[alpha].sub.2]macroglobulin. Clin Chem 1998;44:2471-9.
(9.) Mikolajczyk SD, Marker KM, Millar LS, Kumar A, Saedi MS, Payne JK, et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001;61:6958-63.
(10.) Stenman UH, Leinonen J, Zhang WM. Problems in the determination of prostate specific antigen. Eur J Clin Chem Clin Biochem 1996;34:735-40.
(11.) Schedlich U, Bennets BH, Morris B.I. Primary structure of a human glandular kallikrein gene. DNA 1987;6:429-37.
(12.) Lundwall P,, Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 1987;214:317-21.
(13.) Chapdelaine P, Paradis G, Tremblay RR, Dube JY. High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen. FEBS Lett 1988;236:205-8.
(14.) Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CY, et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 1997;49:857-62.
(15.) Finlay JA, Evans CL, Day JR, Payne JK, Mikolajczyk SD, Millar LS, et al. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immu noassay for hK2 with negligible prostate-specific antigen cross-reactivity. Urology 1998;51:804-9.
(16.) Stenman UH, Paus E, Allard WJ, Andersson I, Andres C, Barnett TR, et al. Summary report of the TD-3 workshop: characterization of 83 antibodies against prostate-specific antigen. Tumour Biol 1999;20:1-12.
(17.) Pettersson K, Piironen T, Seppala M, Liukkonen L, Christensson A, Matikainen MT, et al. Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-a,antichymotrypsin complex. Clin Chem 1995; 41:1480-8.
(18.) Nilsson 0, Peter A, Andersson I, Nilsson K, Grundstrom B, Karlsson B. Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA. Eur Urol 1997;31:178-81.
(19.) Corey E, Wegner SK, Corey MJ, Vessella RL. Prostate-specific antigen: characterization of epitopes by synthetic peptide mapping and inhibition studies. Clin Chem 1997;43:575-84.
(20.) Piironen T, Villoutreix BO, Becker C, Hollingsworth K, Vihinen M, Bridon D, et al. Determination and analysis of antigenic epitopes of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modeling. Protein Sci 1998;7:259-69.
(21.) Michel S, Deleage G, Charrier JP, Passagot J, Battail-Poirot N, Sibai G, et al. Anti-free prostate-specific antigen monoclonal antibody epitopes defined by mimotopes and molecular modeling. Clin Chem 1999;45:638-50.
(22.) Black MH, Grass CL, Leinonen J, Stenman UH, Diamandis EP. Characterization of monoclonal antibodies for prostate-specific antigen and development of highly sensitive free prostate-specific antigen assays. Clin Chem 1999;45:347-54.
(23.) Worthington J, Morgan K. Epitope mapping using synthetic peptides. In: Wisdom GB, ed. Peptide antigens, 1st ed. New York: Oxford University Press, 1994:181-216.
(24.) Cortese R, Monaci P, Luzzago A, Santini C, Bartoli F, Cortese I, et al. Selection of biologically active peptides by phage display of random peptide libraries. Curr Opin Biotechnol 1996;7:616-21.
(25.) Craig L, Sanschagrin PC, Rozek A, Lackie S, Kuhn LA, Scott JK. The role of structure in antibody cross-reactivity between peptides and folded proteins. J Mol Biol 1998;281:183-201.
(26.) Chargelegue D, Obeid OE, Hsu SC, Shaw MD, Denbury AN, Taylor G, et al. A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo. J Virol 1998;72:2040-6.
(27.) Zhang WM, Leinonen J, Kalkkinen N, Dowell B, Stenman UH. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem 1995;41:1567-73.
(28.) Wu P, Leinonen J, Koivunen E, Lankinen H, Stenman UH. Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity. Eur J Biochem 2000;267:6212-20.
(29.) Villoutreix BO, Getzoff ED, Griffin JH. A structural model for the prostate disease marker, human prostate-specific antigen. Protein Sci 1994;3:2033-44.
(30.) Sayle RA, Milner-White EJ. RASMOL: biomolecular graphics for all. Trends Biochem Sci 1995;20:374.
(31.) Leinonen J, Zhang WM, Stenman UH. Complex formation between PSA isoenzymes and protease inhibitors. J Urol 1996;155:1099-103.
(32.) Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson 0, Pettersson K, et al. Prostate-specific antigen in serum occurs predominantly in complex with ai antichymotrypsin. Clin Chem 1991;37:1618-25.
(33.) Bellanger L, Andres C, Seguin P. Epitope mapping of 53 antibodies against prostate-specific antigen. Tumour Biol 1999;20(Suppl 1):18-23.
(34.) Leinonen J, Zhang W-M, Paus E, Stenman U-H. Reactivity of 77 antibodies to prostate specific antigen (PSA) with isoenzymes and complexes of PSA. Tumor Biol 1999;20(Suppl 1):28-34.
(35.) Finlay JA, Day JR, Rittenhouse HG. Polyclonal and monoclonal antibodies to prostate-specific antigen can cross-react with human kallikrein 2 and human kallikrein 1. Urology 1999;53:746-51.
(36.) Wang TJ, Linton HJ, Rittenhouse HG, Wolfert RL. Western blotting analysis of antibodies to prostate-specific antigen: cross-reactivity with human kallikrein-2. Tumour Biol 1999;20(Suppl 1):75-8.
(37.) Van Regenmortel MH. The antigen-antibody reaction. In: Price C, Newman D, eds. Principles and practice of immunoassay. New York: Stockton Press, 1997:13-34.
(38.) Angelopoulou K, Borchert G, Melegos DN, Lianidou E, Lilja H, Diamandis EP. Characterization of the BRCA1-like immunoreactivity of human seminal plasma. Urology 1999;54:753-62.
(39.) Weininger R, Richards F. Combining regions of antibodies. In: Atassis M, ed. Immunochemistry of proteins. New York: Plenum, 1979:123-66.
(40.) Keitel T, Kramer A, Wessner H, Scholz C, Schneider-Mergener J, Hohne W. Crystallographic analysis of anti-p24 (HIV-1) monoclonal antibody cross-reactivity and polyspecificity. Cell 1997;91:811-20.
(41.) Kramer A, Keitel T, Winkler K, Stocklein W, Hohne W, SchneiderMergener J. Molecular basis for the binding promiscuity of an anti-p24 (HIV-1) monoclonal antibody. Cell 1997;91:799-809.
(42.) Parhami-Seren B, Keel T, Reed GL. Sequences of antigenic epitopes of streptokinase identified via random peptide libraries displayed on phage. J Mol Biol 1997;271:333-41.
(43.) Jette DC, Kreutz FT, Malcolm BA, Wishart DS, Noujaim AA, Suresh MR. Epitope mapping of prostate-specific antigen with monoclonal antibodies. Clin Chem 1996;42:1961-9.
(44.) Harris SL, Craig L, Mehroke JS, Rashed M, Zwick MB, Kenar K, et al. Exploring the basis of peptide-carbohydrate cross reactivity: evidence for discrimination by peptides between closely related anti-carbohydrate antibodies. Proc Natl Acad Sci U S A 1997;94: 2454-9.
(45.) Stenman U-H. Immunoassay standardization. In: Price C, Newman D, eds. Principles and practice of immunoassay. New York: Stockton Press, 1997:245-68.
Jari Leinonen, * Ping Wu, and Ulf-Hakan Stenman
 Nonstandard abbreviations: PSA, prostate-specific antigen; hK2, human kallikrein-2; MAb, monoclonal antibody; IFMA, immunofluorometric assay; and TBS, Tris-buffered saline.
Department of Clinical Chemistry, Helsinki University Central Hospital, FIN-0029 Helsinki, Finland.
* Address correspondence to this author at: Department of Clinical Chemistry in Biomedicum, Helsinki University Central Hospital, Haartmaninkatu 8, FIN-00290 Helsinki, Finland. Fax 358-9-4717-1731; e-mail firstname.lastname@example.org.
Received May 27, 2002; accepted August 30, 2002.
Table 1. Amino acid sequences of peptides selected from phage display peptide libraries with MAbs against PSA. (a) MAb(s) Peptide Sequence 5E4 VI-1 CPVDFDFLC 5E4 VI-9 CPRDFEFLC 5E4 VI-12 CPADFEFLC 5E4 and H117 VI-13 CPSVDGGWTC 5E4 and H117 VI-14 CKSMDGGWTC 5E4 and H117 VI-15 CHSACSKHCFVHC H117 VI-18 CTWHWSPEEC H117 and 5E4 VI-20 CPSVDGGWTC H117 and 5E4 VI-21 CHSACSKHCFVYC H117 and 5E4 VI-22 CHSACSKHCFVHC 5A10 and 4G10 I-8 CRPWGSSRC 5A10 and 4G10 I-9 CKSWGSSRC 5A10 and 4G10 I-15 CNLYKVGC 5A10 and 4G10 I-16 CHPYKVGC 4G10 I-19 CSVYPFWHC 4G10 and 5A10 I-30 CRSYPFWMC 4G10 and 5A10 I-31 CVSYPFWKC 4G10 and 5A10 I-32 CAVFPFWRC 4G10 and 5A10 I-33 CVWWWGC 4G10 and 5A10 I-35 CAPWWGC H50 III-1 CSGIAPWLC H50 III-8 CGPGIDSWVC H50 III-9 CGPGIRSWVC H50 III-12 CDYMPLVDNC H50 and 9C5 III-14 CEGIAVWLC H50 and 9C5 III-15 CTRYSGYWVC H50 and 9C5 III-17 CTQMNGYWIC H50 and 9C5 III-20 CLYDHLC H50 and 9C5 III-25 CILLYNDCC 9C5 III-28 CFFGNWNFC 9C5 and H50 III-37 CWNWNLHISC 9C5 and H50 III-38 CYFKNWNFC 9C5 and H50 III-39 CVRSCISDCELRC (a) The sequences of the peptides analyzed further are shown. The peptides were isolated by panning with each MAb or by sequential panning, in which the library was first panned using one MAb, after which the eluate was panned with another related MAb. The peptide sequences were determined by sequencing the relevant part of the viral DNA. MAbs 5E4 and H117 belong to epitope group VI, MAbs 5A10 and 4G10 to group I, and MAbs H50 and 9C5 to group III (16). The sequences of all peptides isolated (n = 100) are available as a data supplement with the online version of this article at http://www/clinchem/org/ content/vol48/issue12/. Table 2. Reactivity of group VI MAbs with peptides isolated by panning sequentially with MAbs 5E4 and H117. (a) Peptide MAb VI-13 VI-14 VI-15 PSA-Eu3 27 9831 -- 12730 32 410 29 -- -- -- 209 062 34 476784 -- 14329 310 266 56 (H117) 472197 485780 396210 330 600 65 -- -- -- 303 059 67 20575 -- 65068 55 636 75 -- -- -- 37 636 79 (5E4) 337648 246281 217960 378 440 210 -- -- -- 348 434 214 29145 1391404 53310 389 005 218 -- -- -- 327 034 221 -- -- -- 259 856 225 1266 -- 2072 377 816 (a) The binding of phage was measured by IFMA using each of the PSA MAbs on solid phase and anti-phage antibody as tracer. The results are expressed in europium fluorescence units (cps) and represent mean values of duplicate measurements. For comparison, the response (cps) obtained by adding 10 ng of europium-labeled PSA to wells coated with each MAb is shown. A result is indicated by (-) when the response was below the detection limit of the assay (1125 cps; defined as binding of phage containing an unrelated peptide to MAbs +3 SD). The assay CVs of phage binding IFMAs were 5-20%. Table 3. Reactivity of group III MAbs with peptides isolated by panning sequentially with MAbs H50 and 9C5. (a) Peptide MAb III-14 III-15 III-17 III-20 III-25 31 4571 4767 10 417 -- -- 36 -- -- -- -- -- 57 (H50) 69 591 14 927 31 185 466 040 144 901 63 1141 2467 -- -- 15 737 64 -- -- -- 1157 -- 66 -- -- -- -- -- 72 -- 2684 -- -- -- 82 (9C5) -- -- -- -- -- 84 -- -- -- -- -- 88 -- -- -- -- -- 89 -- -- -- -- -- 212 -- -- -- -- -- 224 -- 6128 -- 1855 2978 229 -- 2808 -- -- -- Peptide MAb III-37 III-38 III-39 PSA-Eu 31 -- 6172 -- 289 969 36 -- -- -- 213 806 57 (H50) -- -- -- 110 126 63 17 555 -- -- 256 147 64 -- -- -- 147 172 66 -- -- -- 213 319 72 -- -- -- 157 672 82 (9C5) 101 174 205 955 108 687 215 199 84 -- -- -- 186 125 88 -- -- -- 26 488 89 1463 -- -- 36 888 212 -- -- -- 192 330 224 -- -- -- 71 934 229 -- -- -- 166 244 (a) The assay was as described in footnote a of Table 2.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Proteomics and Protein Markers|
|Author:||Leinonen, Jari; Wu, Ping; Stenman, Ulf-Hakan|
|Date:||Dec 1, 2002|
|Previous Article:||Simple method for quantification of Bence Jones proteins.|
|Next Article:||High-throughput quantification of lysophosphatidylcholine by electrospray ionization tandem mass spectrometry.|